Renovorx reports third quarter 2022 financial results

Los altos, calif.--( business wire )--renovorx, inc. (nasdaq: rnxt), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary renovorx trans-arterial micro-perfusion (renovotamp®) therapy platform, today reported its financial results for the quarter ended september 30, 2022.
RNXT Ratings Summary
RNXT Quant Ranking